Durgical
EN
Open the app

Following stable chronic disease and changing treatment over time

  • Approach

Most chronic care is the routine review visit: measure a few things, check adherence and change treatment at the right time, up or down.

Updated

What it is

The planned follow-up of stable chronic disease (hypertension, diabetes, CKD, COPD and others): agreeing individual targets, measuring the few things that show whether they are met, and deciding at each visit whether to keep, intensify, simplify or reduce treatment. Targets and treatment are revised with the person as age, frailty, other diseases and priorities change.

Key facts

  • Follow-up interval tracks stability: soon after any change or when off target; every few months once stable at target, with laboratory tests at the intervals the disease guideline sets.
  • Measure what changes decisions: blood pressure measured properly (and home readings), weight, HbA1c, kidney function and albuminuria, lipids when they will alter treatment, symptoms and function; avoid tests that change nothing.
  • HbA1c reflects roughly the last three months, so rechecking it sooner after a change does not show the full effect.
  • Treat to target means a target agreed with the person: tighter for a young person with long life expectancy, looser for a frail older adult in whom hypoglycaemia or falls are the bigger risk.
  • Adherence has many causes (WHO): the condition, the therapy (complexity, side effects), the patient, the health system (access, cost, delivery of medicines) and social and economic factors; blame is not one of the tools.
  • Treatment burden adds up in multimorbidity (NICE NG56): appointments, tests, medicines and self-care; the number of regular medicines is a simple marker.
  • Shared decision-making: explain the options, their benefits and harms in plain absolute terms, and choose with the person according to what matters most to them.

Step by step in the consultation

  1. Don Álvaro (made up), 64, hypertension and type 2 diabetes, comes for his control visit. Start with what changed: symptoms, admissions, new medicines, worries.
  2. Measure the agreed few: blood pressure seated and repeated plus his home readings, weight, feet; review HbA1c, creatinine with eGFR and urine albumin.
  3. Compare with the targets agreed last time: blood pressure and HbA1c are both above target for the second visit in a row.
  4. Before turning the dial, ask without judgement how he takes them: he skips the evening pill (it makes him urinate at night) and runs out before refills.
  5. Fix the cause first: move to a once-daily scheme or a fixed-dose combination, align refills, ask about anti-inflammatory use and salt.
  6. If still above target with good adherence and correct readings, intensify one step, agreed with him, and book an earlier review.
  7. Second case: Doña Inés, 83, frail, has a very low HbA1c on a sulfonylurea and dizziness on standing. Here the move is de-intensifying, not more.
  8. Write the plan: targets, the change and why, the next visit and tests, warning signs; flag him for tracing if he misses the visit.

At the review visit: keep, intensify, simplify or de-intensify?

What you findWhat it usually meansMove
At target, well, no harmsThe plan worksKeep; same interval; reinforce self-care
Above target, readings reliable, takes treatment as agreedTreatment is not enoughIntensify one step; earlier review
Above target, not taking treatment as agreedA barrier: side effect, cost, complexity, belief, accessFind the barrier; simplify the scheme before adding
Below target or harmed by treatmentToo much: hypoglycaemia, falls, low blood pressureDe-intensify; recheck soon
Goals changed: frailty, limited life expectancy, heavy treatment burdenThe old target no longer fitsReset the target with the person; deprescribe

In practice

  • Every review visit is a chance to ask what matters to the person now and whether the plan still fits their life.
  • After a hospital discharge or a new diagnosis, review the whole plan, not only the disease that changed.
  • In multimorbidity, prioritise: agree which conditions and treatments matter most and which can be eased to lower treatment burden.
  • In Colombia, the MinSalud lineamientos for cardiovascular disease, diabetes and chronic kidney disease ask services for team care, simple treatment schemes with clear control targets, periodic follow-up and tracing of people who miss controls; risk is first detected at the periodic assessment of Res. 3280 de 2018.
  • Decreto 1652 de 2022 exempts diagnoses with regular prescriptions from cuotas moderadoras and copagos to support adherence; cost and refill problems are still worth asking about.

Common pitfalls

  • Intensifying on a single high office reading: white-coat effect and poor technique are common; repeat and use home or ambulatory readings.
  • Adding a drug before asking about adherence: the new drug joins the ones not being taken.
  • Clinical inertia: noting «above target, continue» visit after visit.
  • Never de-intensifying: targets set at 55 are kept at 85 despite falls and hypoglycaemia.
  • Ordering every test at every visit: tests that do not change a decision add cost and burden.
  • Changing several things at once, so nobody can tell what helped or harmed.

Common traps

  • Above target means the drug failed: first check the reading and whether the treatment is taken as agreed; poor adherence and poor measurement are common causes
  • Treat to target means the tightest target for everyone: targets are individual, and in frail older adults tight control can cause more harm (hypoglycaemia, falls) than benefit
  • Stable means no change needed: a stable person can still need de-intensifying when the treatment is causing harm or no longer fits their goals
  • Adherence is the patient's responsibility alone: WHO describes five groups of causes, including the therapy itself and the health system; simplifying and fixing access often works better than advice
  • More visits and tests mean better care: follow-up should match stability, and each test should be able to change a decision

Test yourself

Think of the answer, then tap the question to see it.

A man's office blood pressure is above target for the second time. What two checks come before adding a medicine?

Whether the reading is reliable (technique, repeated or home readings) and whether he takes the treatment as agreed, asked without judgement.

An 83-year-old frail woman has a very low HbA1c on a sulfonylurea and dizziness on standing. What is the right move?

De-intensify: relax her target and reduce or stop the drug that causes hypoglycaemia, then review soon; tight control is harming her.

Why is HbA1c not rechecked two weeks after a change in diabetes treatment?

It reflects glucose over roughly the previous three months, so the full effect of the change is seen only after about three months.

What is clinical inertia, and why does it matter?

Failing to start or intensify treatment when a person stays off target; it is common and leaves people with poor control for long periods.

Why is a fixed-dose combination or once-daily scheme often tried before adding another drug?

Complexity is a leading cause of poor adherence; simplifying can bring the person to target without adding a new medicine and its harms.

Add to my cards (5)

Elsewhere in DurgiPedia

Connections

← All of family medicine

Educational content on the family-medicine and primary-care approach. Not a clinical or legal guide: current Colombian care pathways and rules are in the official sources.

Sources: Multimorbidity: clinical assessment and management (NICE guideline NG56) (National Institute for Health and Care Excellence (NICE), 2016); Adherence to long-term therapies: evidence for action (World Health Organization, 2003); Clinical Inertia in the Management of Type 2 Diabetes Mellitus: A Systematic Review (Medicina, Kaunas) (Europe PMC, 2023); Lineamientos para la gestión territorial integral de la salud pública orientados a la prevención y control de la enfermedad cardiovascular, la diabetes mellitus y la enfermedad renal crónica (Ministerio de Salud y Protección Social, Colombia, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.